• Archives of Pharmacal Research
• /
• 제18권5호
• /
• pp.332-335
• /
• 1995

The angiogenic activity of Aloe vera (Aloe baradensis), known as a good healing plant, was investigated. We have extracted and fractionated dichloromethane extract (G1M1D1) and methanol soluble fraction of dichloromethane extract (G1M1D1M1) which contain low-molecular weight substances of Aloe vera gel. G1M1D1 and G1D1M1 fractions induced a radially arranged, spoke-sheel-like vasculature in chick embryo chorioallantoic membrane (CAM) assay. The angiogenic activity was dose-dependent and the angiogenic pattern in the CAM assay. The angiogenic activity was dose-dependent and the angiogenic pattern in the CAM assay was very similar to that of phorbol 12-myristate-13-acetate (PMA) used as a positive control. The modified CAM assay, e simple and accurate quantitating method, was used to quntitate the angiogenic activity of G1D1M1 fraction. Application of G1M1D1M1 fraction ($100\mug/egg$) resulted in much more intense angiogenesis than in control while slightly less intense angiogenesis than in PMA (100 ng/egg).

• 생명과학회지
• /
• 제14권1호
• /
• pp.26-31
• /
• 2004

본 연구는 redox regulator로 알려 진 Ref-1 (Redox factor-1)과 결합하는 새로운 단백질을protein-protein interaction의 원리를 이용한 방법인 yeast two-hybrid assay로 검색, 동정하고, 검색된 단백질의 in vitro, in vivo 기능을 규명하는 데 그 목적을 두고, mouse 11-day Embryo cNA library를 prey로, full length REF-1을 bait로 하여 yeast strain 인 HF7C에 cotransformatiom시킨 후 histidine, leucine, tryptophan이 결핍된 SD plate에서 키워 자란 yeast transformants를 $\beta$-galactosidaseassay하여 screening하여 분리한 세 개의 clone중 한 clone이 DNA sequencing으로 확인한 결과 mouse thioredoxin임을 확인하였다.

• 한국식품과학회지
• /
• 제51권2호
• /
• pp.141-146
• /
• 2019

본 연구에서는 꽃송이버섯 소수성 추출물(SCF4)의 항혈관신생활성을 혈관내피세포인 HUVECs을 사용하여 확인하였다. 그 결과, SCF4는 세포 독성을 나타내지 않는 $5-25{\mu}g/mL$의 농도에서 VEGF에 의해 유도된 혈관내피세포 증식을 유의적으로 감소시켰을 뿐만 아니라, 혈관내피세포 침윤성과 관 형성 능력을 농도의 존적으로 감소시켜 in vitro 혈관신생을 효과적으로 저해함을 확인하였다. 또한, SCF4는 독성을 나타내지 않고 CAM의 혈관신생을 저해함으로써, in vivo 혈관신생을 효과적으로 저해함을 확인하였다. 마지막으로 SCF4가 혈관신생을 유도하는 주요 신호전달 경로인 VEGFR2, AKT 및 ERK1/2의 전체 단백질 발현 수준의 변화없이 인산화를 저해함을 확인하였다. 따라서, 본 연구는 꽃송이버섯 소수성 추출물이 혈관신생 저해활성을 나타내고 이러한 현상은 VEGFR2 신호전달경로의 억제를 통해 진행됨을 입증하여, 혈관신생 관련 질환 예방 및 치료를 위한 천연물 소재로서의 적용 가능성을 새롭게 제시하였다.

• 대한암한의학회지
• /
• 제11권1호
• /
• pp.75-93
• /
• 2006

Jiaweicitaowan (JWCTW) has been used to inhibit recurrence and metastasis of cancer in clinical practice. Further study has shown its anti-metastatic and anti-angiogenic effects. By applying in vitro and in vivo anti-angiogenic evaluation model, the author assayed the each ingredients of JWCTW. The author performed the following experiments and the results are listed as below: Cell viability assay showed that the viability was almost identical between that of the control and that of the ingredients extract 40 ${\mu}g/m{\ell}$ treated, except of hexane fraction of Curcumae Radix (40 ${\mu}g/m{\ell}$, 2.0% of control), ethylacetate fraction (40 ${\mu}g/m{\ell}$, 26.7%), butanol fraction (20 ${\mu}g/m{\ell}$, 87.2%; 40 ${\mu}g/m{\ell}$, 12.5%) of Cremastrae appendiculatae Tuber, water fraction of Persicae Semen (40 ${\mu}g/m{\ell}$, 82.7%), ethylacetate fraction of Hippocampus (40 ${\mu}g/m{\ell}$, 85.3%). The results of gelatin zymogram assay showed that the ingredients of JWCTW decreases the gelatinolytic activity of MMP-9 from ECV304, at the concentration of 10 ${\mu}g/m{\ell}$. In in vitro invasion assay, the ingredients of JWCTW effectively inhibited the invasion of cancer cells as compared with the control (+PMA) groups. In capillary-like tube formation assay, the hexane and ethylacetate fractions of Curcumae Radix, Cremastrae appendiculatae Tuber and Persicae Semen showed the dramatic inhibition effects on tube formation of ECV304 at the concentration of 40 ${\mu}g/m{\ell}$. In ex vivo rat aortic ring assay, the hexane and ethylacetate fractions of Curcumae Radix, Cremastrae appendiculatae Tuber and Persicae Semen showed the inhibition effects on angiogenesis of rat aorta at the concentration of 40 ${\mu}g/m{\ell}$. According to the above research, the anti-angiogenic effects of the ingredients of JWCTW was proved and it suggested that the more effective prescription for anti angiogenesis could be developed.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권8호
• /
• pp.3977-3982
• /
• 2012

Inhibitors of histone deacetylase activity are emerging as a potentially important new class of anticancer agents. In this study, we assessed the anticancer effects of valproic acid (VPA) on ovarian cancer in vitro and in vivo. Cultured SKOV3 cells were treated by VPA with different concentrations and time, then the effects on cell growth, cell cycle, apoptosis, and related events were investigated. A human ovarian cancer model transplanted subcutaneously in nude mice was established, and the efficacy of VPA used alone and in combination with diammine dichloroplatinum (DDP) to inhibit the growth of tumors was also assessed. Proliferation of SKOV3 cells was inhibited by VPA in a dose and time dependent fashion. The cell cycle distribution changed one treatment with VPA, with decrease in the number of S-phase cells and increase in G1-phase. VPA could significantly inhibit the growth of the epithelial ovarian cancer SKOV3 cells in vivo without toxic side effects. Treatment with VPA combined with DDP demonstrated enhanced anticancer effects. The result of flow cytometry (FCM) indicated that after VPA in vitro and in vivo, the expression of E-cadherin was increased whereas vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) were decreased. This study suggests that VPA could be a novel attractive agent for treatment of ovarian cancer.

• Bulletin of the Korean Chemical Society
• /
• 제25권12호
• /
• pp.1863-1868
• /
• 2004

Kringle 5 (K5), located outside of angiostain (K1-4) in human plasminogen, displays more potent antiangiogenic activity on endothelial cell proliferation than angiostatin itself. Using a yeast two-hybrid system in vivo, we have recently identified Rgl2 (guanine nucleotide dissociation stimulator (RalGDS)-like factor 2) as a binding protein of human K5. In order to confirm in vitro protein interaction between K5 and Rgl2, we developed bacterial recombinant expression systems for them. K5 and Rgl2 proteins were expressed in high yields and purified into pure forms with His tags and GST fusion, respectively. GST-pull down experiments clearly demonstrated that K5 interacts specifically with Rgl2 in vitro. These results indicate that Rgl2 functions as a receptor protein for K5 in vitro as well as in vivo, leading to anti-angiogenesis through regulating Ras signaling pathways.

• Biomaterials and Biomechanics in Bioengineering
• /
• 제1권1호
• /
• pp.41-50
• /
• 2014

Gold nanorod's exceptional light to heat transduction is a robust phonomenon that has been extensively verified. The phenomenon is a trait from which many novel applications across disciplines have been proposed. In this investigation, the feasibility of utilizing heat harvested from such photothermal method to combat cancer is presented. Using non-invasive laser methods, an in vivo study is conducted on mouse ear tumors administered with gold nanorods (Au NRs). An emphasis is placed on monitoring the tumor developments after photothermal treatments, over time. The findings reveal significant tumor growth surpression at a threshold laser power of $0.6W/cm^2$ lasting 2 minutes; this energy also brought about dramatic size reduction in treated tumors. Furthermore, the apparent formation of an eschar over the laser treated region indicates extensive hemorrhagic necrosis of the tumor tissue; a phenomenon implicative to the inhibition of angiogenesis.

• Journal of Ginseng Research
• /
• 제47권2호
• /
• pp.173-182
• /
• 2023

Cancer is a global public health issue that becomes the second primary cause of death globally. Considering the side effects of radio- or chemo-therapy, natural phytochemicals are promising alternatives for therapeutic interventions to alleviate the side effects and complications. Ginsenoside Rh2 (GRh2) is the main phytochemical extracted from Panax ginseng C.A. Meyer with anticancer activity. GRh2 could induce apoptosis and autophagy of cancer cells and inhibit proliferation, metastasis, invasion, and angiogenesis in vitro and in vivo. In addition, GRh2 could be used as an adjuvant to chemotherapeutics to enhance the anticancer effect and reverse the adverse effects. Here we summarized the understanding of the molecular mechanisms underlying the anticancer effects of GRh2 and proposed future directions to promote the development and application of GRh2.

• 동의생리병리학회지
• /
• 제20권4호
• /
• pp.825-829
• /
• 2006

Rhus verniciflua Stokes has been used for treatment of blood stasis and abdominal mass in Oriental medicine. Rhus verniciflua Stokes has been experimentally reported to exert antioxidant, antiproliferative, antithrombotic and apoptotic activities. In the present study, the antiangiogenic and in vivo antitumor activities of aqueous extract of processed Rhus verniciflua Stokes (Nexia) by heat were examined to elucidate its anticancer mechanism. Nexia showed weak cytotoxiicty against human umbilical vein endothelial cells (HUVEC) and Lewis lung carcinoma cells (LLC) with IC50 of${\sim}200\;{\mu}g/ml\;and\;>200\;{\mu}g/ml$, respectively. Nexia significantly inhibited the proliferation and migratory activity in vascular endothelial growth factor(VEGF) treated HUVEC. Furthermore, Nexia effectively suppressed the tumor volume in A549 nonsmall lung cancer bearing athymic nude mice, CanN. Cg-Foxn 1nu/CrljBgi up to 40.7% as well as tumor weight incised from LLC cells innoculated into the flank of C57BL/6 mice up to -50% compared with untreated control at a dose of 300 mg/kg. Taken together, these results suggest that processed Rhus verniciflua Stokes may inhibit the growth of Lewis lung carcinoma cells partly via inhibition of angiogenesis and can be potently applied to angiogenesis dependent cancers. However, it still needs a further research on molecular mechanism, angiogenesis animal study and clinical trial in future.

• 생명과학회지
• /
• 제22권9호
• /
• pp.1224-1230
• /
• 2012

항암화학요법제는 의약품 시장 중 가장 큰 시장의 하나이며, 세계적으로 수많은 연구와 신약의 개발이 진행되고 있다. 그러나 암 세포 뿐만 아니라 정상세포와 조직에 대한 독성과 내성으로 인해 심각한 부작용이 지속되어, 최근 신혈관형성 억제와 천연물 유래의 암 치료제 개발이 많은 관심을 얻고 있다. 본 연구에서는 오미자의 활성성분 중 하나인 Gomisin A의 종양성장 및 전이억제 효과와 이들의 작용기전에 대해 확인하고자 하였다. Gomisin A의 종양성장 억제활성은 B16BL6 cell line을 C57/BL6 mice의 피하에 주입하여 유도된 종양모델을 활용 하였으며, Gomisin A 10 ${\mu}g/ml$, 100 ${\mu}g/ml$에서 양성 대조군에 비해 각각 $80.5{\pm}8.1%$, $96.2{\pm}2%$의 유의한 억제활성을 나타내었다. Gomisin A의 암세포에 대한 직접적인 독성은 MTT assay를 통해 확인하였고, 정상세포(HUVECs)와 종양세포주(A549, B16BL6, Du145, Huh7)에 대한 유의한 독성은 관찰되지 않았다. 종양조직에 의해 유도되는 신혈관형성 억제능은 C57/BL6 mice에 배양된 B16BL6 cell line을 피하주사하여 종양조직을 형성하고, 이들이 유도하는 신생혈관에 대한 Gomsin A의 억제활성을 확인하였다. Gomisin A를 10 ${\mu}g$/head와 100 ${\mu}g$/head에서 신혈관형성 억제활성은 양성 대조군에 비해 각각 $151{\pm}16.9%$, $98.5{\pm}29.5%$의 유의한 감소활성을 나타내었다. 종양전이 억제활성은 B16BL6 cell line을 C57/BL6 mice 미정맥에 주입하여 in vivo 폐전이 모델을 만들고 폐에 전이된 종양의 colony를 측정하여 확인하였다. Gomisin A의 농도 10 ${\mu}g$/head, 100 ${\mu}g$/head에서 각각 양성 대조군에 비해 $13.5{\pm}8.56%$, $58.3{\pm}9.12%$의 전이 억제활성을 나타내었다. 또한 Gomisin A는 B16BL6 cell line이 세포외기질에 대한 부착능을 유의하게 감소시킴을 확인하였다. 이러한 결과는 Gomisin A의 종양성장 억제활성이 암세포에 대한 직접적인 독성에 의한 것이 아닌 신혈관형성 억제에 의한 것이며, 또한 종양 전이 억제 활성을 나타냄으로서 향후, 암 예방 및 치료제 개발의 선도물질을 제공할 수 있음을 확인하였다. 본 연구는 오미자의 주요 생리활성 물질인 Gomisin A의 종양성장 억제 활성과 전이억제 활성을 규명하고자 하였다. Gomisin A가 종양성장 억제활성이 있음을 확인하였고, 이러한 효과는 종양세포에 대한 직접적인 독성에 의한 것이 아니라, 종양조직에 의해 유도되는 신혈관형성 저해 활성에 의해 나타나는 것을 규명하였다. 이러한 결과는 대부분의 항암화학요법제가 가지는 독성작용을 극복하고, 선택적인 종양성장 억제제로서의 개발 가능성을 시사하여 주고 있다. 또한 Gomisin A는 종양세포의 세포외기질 부착억제활성을 통해 암 전이 억제활성을 나타냄을 확인하였다. 지금까지의 결과는, Gomisin A를 활용한 부작용이 적으며 효과적인 암 치료제 개발의 선도 물질로서 활용 가능성을 나타내 주고 있으며, 또한 고 기능성 식품 및 화장품의 개발에 활용이 가능할 것이다. 그러나, 향후 종양 면역활성, 암세포 자살 유도능과 같은 다양한 부분의 연구가 수반되어야 할 것이다.